Fennec (FENC) Q1 2026: PEDMARK Sales Surge 73% as Commercial Expansion Unlocks New Patient Access
Fennec Pharmaceuticals delivered a breakout Q1 with net product sales up sharply, propelled by expanded commercial reach and accelerating adoption of PEDMARK in adolescent and young adult oncology. Operational leverage is building as field force investments gain traction and new clinical data broadens the addressable market. With durable demand signals and a solid cash position, Fennec enters a pivotal growth phase, but execution on label expansion and global launches remains the key watchpoint.
Summary
- Commercial Expansion Drives Demand: Newly onboarded sales force and Project Ignite initiatives are materially increasing prescriber engagement and patient access.
- Clinical Adoption Deepens: PEDMARK utilization is broadening across tumor types and care settings, with conversion and adherence rates hitting new highs.
- Strategic Pipeline Progress: Investigator-initiated trials and global launches set the stage for further market expansion in 2026 and beyond.
Business Overview
Fennec Pharmaceuticals develops and commercializes PEDMARK, a first-in-class therapy approved to prevent cisplatin-induced ototoxicity (CIO, chemotherapy-related hearing loss) in pediatric patients with solid tumors. The company’s revenue is driven by U.S. sales of PEDMARK, supported by its proprietary patient support platform, Fennec Hears, and partnerships for ex-U.S. commercialization, notably with Norgine in Europe. Major segments include U.S. commercial operations, global clinical development, and international licensing/royalty streams.
Performance Analysis
Fennec posted a transformative quarter, with net product sales rising to $15.1 million, up 73% year-over-year, marking the sixth consecutive quarter of sequential revenue growth since the overhaul of its commercial leadership. The company attributes this acceleration to the successful execution of Project Ignite—an initiative launched in late 2025 to expand the field force by 14 new territories and four additional frontline managers, sharply increasing prescriber reach from 1,300 to over 5,000 targets.
Operational metrics confirm the strategy is working: Completed infusions through Fennec’s full-service hub, Fennec Hears, grew 48% sequentially, while conversion rates and adherence both reached 80% for the first time. The mix of in-office and at-home infusions remains balanced at 50-50, reflecting strong flexibility in patient delivery. Demand in April alone equaled more than half of total Q1 Fennec Hears volume, signaling a robust Q2 pipeline. SG&A growth, driven by commercial investments, pushed operating expenses higher, but positive operating cash flow and a $40 million cash balance provide ample runway for continued scaling.
- Field Force Expansion Impact: New sales territories are already generating prescriptions, with early signs of productivity ramping ahead of schedule.
- Durable Demand Across Tumor Types: Testicular, cervical, and head and neck cancers remain foundational, while academic and community prescriber adoption is broadening.
- Operational Leverage Emerging: Fixed cost base and growing revenues are expected to drive operating income growth in upcoming quarters.
Underlying growth is balanced between new account additions and deepening utilization within established accounts. The business is now positioned to benefit from both top-down (GPO integration) and bottom-up (field sales) commercial strategies.
Executive Commentary
"We are encouraged by our strong start to the year and believe 2026 is a defining period for Fennec. Our conviction is rooted in the progress across many multiple fronts. We've made important strategic enhancements to our business for 2026 that are strengthening our execution across the organization and positions us to continue to build momentum as the year unfolds."
Jeff Hackman, Chief Executive Officer & Board Member
"The expansion of our customer-facing team has allowed us to reach with greater frequency a larger prescriber target base, increasing from 1,300 to now over 5,000 targets. We know the AYA market is promotionally sensitive, and effectively communicating the unmet need around CIO is our number one priority. This creates a pathway for practices to help change the standard of care for all appropriate patients receiving cisplatin."
Terry Evans, Chief Commercial Officer
Strategic Positioning
1. Commercial Footprint Transformation
Project Ignite, a commercial expansion initiative, has fundamentally reshaped Fennec’s go-to-market strategy. By adding new territories and managers, the company has dramatically increased its prescriber reach and frequency, which is critical in a promotionally sensitive market like adolescent and young adult (AYA) oncology. Early evidence shows this is translating to both new account wins and greater depth in existing accounts.
2. Integrated Patient Support as a Differentiator
Fennec Hears, the company’s full-service patient support hub, is a key operational lever, simplifying access, driving higher conversion rates, and supporting both in-office and at-home infusions. With conversion and adherence rates now at 80%, Fennec is demonstrating that its high-touch model is not only driving volume but also building durable relationships with prescribers and patients.
3. Clinical Expansion and Evidence Generation
Investigator-initiated trials (ISTs) are expanding PEDMARK’s clinical footprint into new tumor types and older populations. Recent studies in head and neck and testicular cancers, as well as multiple ASCO presentations, are building the real-world evidence base needed to support guideline inclusion and future label expansion. These efforts are also catalyzing commercial adoption within participating institutions.
4. International Growth Platform
Partnership with Norgine, Fennec’s ex-U.S. commercialization partner, is expected to launch PEDMARK in nearly ten new markets in 2026. While near-term milestones are delayed, management sees 2026 as the foundational year for international royalty and milestone ramp, with over $200 million in potential milestones tied to sales thresholds.
5. Lifecycle Management and Pipeline Optionality
Management is actively pursuing lifecycle management, leveraging IST data to target label expansion for PEDMARK into additional tumor types and adult populations. The expanded commercial infrastructure also positions Fennec to potentially in-license or acquire complementary assets, further diversifying its portfolio and revenue base.
Key Considerations
Fennec’s Q1 results underscore a business at a strategic inflection point, with commercial execution, clinical expansion, and operational leverage converging to drive durable growth. The next phase will test the scalability of its model and ability to translate clinical momentum into regulatory and guideline wins.
Key Considerations:
- Sales Force Ramp Trajectory: Productivity from new hires is already visible, but full impact will be realized in the second half as field teams mature.
- Clinical Data as a Commercial Catalyst: Ongoing ISTs and ASCO presentations are critical for expanding PEDMARK’s addressable market and supporting payer and guideline adoption.
- International Launch Execution: Near-term royalty and milestone timing from Norgine launches remains a key variable for financial upside.
- Fixed Cost Leverage: With a predominantly fixed cost base, incremental revenue growth should drive outsized operating income gains.
- Pipeline and Business Development Flexibility: Management is open to layering in additional assets, leveraging its expanded commercial platform.
Risks
Key risks include the pace of prescriber adoption in new territories, the ability to convert clinical data into expanded indications or guideline support, and timing of ex-U.S. royalty streams. Regulatory delays, competitive entrants, or slower-than-expected productivity ramp from new hires could pressure near-term results. Management’s guidance on cash sufficiency is based on current operating plans and assumes continued revenue momentum.
Forward Outlook
For Q2 2026, Fennec expects:
- Continued sequential sales growth, with April demand already exceeding 50% of Q1’s total Fennec Hears volume.
- Conversion and adherence rates to remain at or above 80% as operational refinements take hold.
For full-year 2026, management maintained guidance:
- Approximately $50 million in cash operating expenses, with over 60% front-loaded in H1.
- Cash, cash equivalents, and projected PEDMARK revenues sufficient to fund current operating plans.
Management highlighted several factors that will shape the year:
- Full productivity from the expanded sales force is expected in the second half.
- International launches and clinical data readouts are anticipated catalysts for broader adoption and potential label expansion.
Takeaways
Fennec’s Q1 marks a step-change in commercial execution, with operational investments and clinical initiatives converging to drive demand and set the stage for broader market penetration.
- Commercial Expansion Accelerates Growth: Field force investments and cross-functional engagement are translating into record enrollments and deeper account penetration.
- Clinical and Operational Leverage: Real-world evidence from ISTs and strong patient support infrastructure are reinforcing adoption and market durability.
- Global and Pipeline Upside: International launches and lifecycle management efforts provide optionality, but execution on these fronts will be critical for sustaining momentum.
Conclusion
Fennec enters mid-2026 with momentum on multiple fronts: commercial, clinical, and operational. The company’s ability to sustain this growth, convert clinical data into expanded indications, and execute on global launches will define its long-term value creation trajectory.
Industry Read-Through
Fennec’s results highlight the critical role of commercial scale and integrated patient support in rare disease and specialty pharma markets. The rapid impact of sales force expansion and hub services offers a playbook for peers targeting promotionally sensitive, high-unmet-need categories. Real-world evidence generation through ISTs is increasingly central to driving both payer and prescriber adoption, especially for therapies with initial narrow labels. The evolving mix of in-office and at-home infusion models also signals the importance of delivery flexibility in oncology. For other specialty pharma and biotech companies, Fennec’s trajectory reinforces the need for synchronized commercial, clinical, and operational execution to unlock durable growth and maximize asset value.